[AGRX] Agile Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 200.03 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 6.62 Change: 0.07 (1.07%)
Ext. hours: Change: 0 (0%)

chart AGRX

Refresh chart

Description: Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.74 M EPS-1 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.67
P/E To EPS Growth P/S P/BV4.1 Price/Cash Per Share
Price/Free Cash Flow-13.7 ROA-37.05% ROE-52.21% ROI
Current Ratio11.29 Quick Ratio Long Term Debt/Equity0.31 Debt Ratio0.1
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities19.52 M Cash From Investing Activities-190 K Cash From Operating Activities-5.65 M Gross Profit
Net Profit-8.54 M Operating Profit-8.01 M Total Assets68.7 M Total Current Assets54.36 M
Total Current Liabilities4.81 M Total Debt15.12 M Total Liabilities19.94 M Total Revenue
Technical Data
High 52 week5.37 Low 52 week2.04 Last close3.28 Last change1.86%
RSI30.73 Average true range0.43 Beta0.89 Volume99.56 K
Simple moving average 20 days-4.15% Simple moving average 50 days-22.43% Simple moving average 200 days-16.6%
Performance Data
Performance Week15.49% Performance Month-32.51% Performance Quart-38.23% Performance Half-17.59%
Performance Year28.13% Performance Year-to-date21.93% Volatility daily14.71% Volatility weekly32.9%
Volatility monthly67.42% Volatility yearly233.55% Relative Volume435.39% Average Volume499.87 K
New High New Low


2019-09-10 09:00:01 | Agile Therapeutics AGRX Upgraded to Strong Buy: Here's What You Should Know

2019-09-06 07:30:00 | Agile Therapeutics to Present at Upcoming Investor Conferences

2019-09-05 10:12:29 | 3 “Strong Buy” Biotech Stocks Ahead of FDA Verdicts

2019-08-30 09:45:08 | Agile AGRX Stock Could Be Ready to Break Out

2019-08-22 10:50:02 | New Strong Buy Stocks for August 22nd

2019-08-08 16:15:00 | Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters

2019-08-02 09:05:00 | Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock

2019-08-01 16:01:00 | Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

2019-08-01 08:00:00 | Agile Therapeutics Reports Second Quarter 2019 Financial Results

2019-07-18 07:30:00 | Agile Therapeutics Appoints Chief Financial Officer

2019-06-24 16:15:00 | Agile Therapeutics Announces FDA Advisory Committee Meeting for its Investigational Transdermal Low-Dose Contraceptive Patch, Twirla® AG200-15

2019-05-22 07:00:00 | Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

2019-05-17 07:30:00 | Agile Therapeutics Resubmits New Drug Application NDA for its Transdermal Low-Dose Contraceptive Patch, Twirla®

2019-05-09 08:00:00 | Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

2019-05-03 08:00:00 | Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting

2019-05-02 18:56:37 | Agile Therapeutics: 1Q Earnings Snapshot

2019-05-02 16:15:00 | Agile Therapeutics Reports First Quarter 2019 Financial Results

2019-03-28 08:00:00 | Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK

2019-03-15 08:00:00 | Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress

2019-03-14 12:00:00 | AGRX: Numerous Catalysts in 2019…

2019-03-12 17:52:58 | Agile Therapeutics: 4Q Earnings Snapshot

2019-03-12 16:15:00 | Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-11 08:00:00 | Agile Therapeutics to Present at Upcoming Investor Conferences

2019-03-04 07:30:00 | Agile Therapeutics Announces $7.8 Million Private Placement

2019-02-12 10:30:00 | AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19

2019-02-11 07:30:00 | Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®

2019-02-07 08:00:00 | Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference

2019-01-11 10:45:00 | AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…

2019-01-11 08:38:43 | The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

2019-01-10 16:15:00 | Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance

2018-12-27 07:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

2018-12-18 08:00:00 | Agile Therapeutics to Present at Biotech Showcase 2019

2018-12-13 16:15:00 | Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®

2018-11-13 13:32:53 | Agile Therapeutics Inc NASDAQ:AGRX: Are Analysts Optimistic?

2018-11-05 13:30:00 | AGRX: Awaiting Details of Adhesion Study for Twirla®…

2018-11-02 05:12:31 | Agile Therapeutics: 3Q Earnings Snapshot

2018-11-01 16:15:00 | Agile Therapeutics Reports Third Quarter 2018 Financial Results

2018-10-24 08:00:00 | Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 Twirla® Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning NAFFP

2018-10-23 08:25:00 | New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-22 08:15:00 | Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target

2018-10-16 08:00:00 | Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics

2018-10-10 11:15:00 | AGRX: FDA Provides Path to NDA Resubmission for Twirla®…

2018-10-10 08:00:00 | Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma

2018-10-09 08:00:00 | Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA

2018-09-14 10:04:57 | Does Agile Therapeutics Inc NASDAQ:AGRX Fall With The Market?

2018-09-12 08:00:00 | Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX

2018-09-11 10:35:00 | New Growth Opportunities Jump for 3 Biotech Stocks in 2018

2018-08-29 08:10:00 | Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott — Fundamental Analysis, Key Performance Indications

2018-08-09 09:45:00 | AGRX: Formal Dispute Resolution Continues to Office of New Drugs…

2018-08-03 08:11:27 | Agile Therapeutics: 2Q Earnings Snapshot